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Available online 4 January 2018HIV-Nef activates the myeloid cell-typical tyrosine kinase Hck, but its molecular role in the viral life cycle is not
entirely understood.We found that HIV plasma extracellular vesicles (HIV pEV) containing/10 proteases and Nef
also harbor Hck, and analyzed its role in the context of HIV pEV secretion. Myeloid cells required Hck for the
vesicle-associated release of ADAM17. This could be induced by the introduction of Nef and implied that HIV
targeted Hck for vesicle-associated ADAM17 secretion from a myeloid compartment. The other contents of
HIV-pEV, however, including miRNA and effector protein proﬁles, as well as the presence of haptoglobin
suggested hepatocytes as a possible cellular source. HIV liver tissue analysis supported this assumption, revealing
induction of Hck translation, evidence for ADAM protease activation and HIV infection. Our ﬁndings suggest that
HIV targets Hck to induce pro-inﬂammatory vesicles release and identiﬁes hepatocytes as a possible host cell
compartment.
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One of thewell documented effects of HIVNef is the activation of the
tyrosine kinase Hck by interaction of its PxxP motif with the Hck SH3
domain (Saksela et al., 1995). This opens an intramolecular lock and
constitutes the ﬁrst step in the activation of the kinase (Lee et al.,
1995, 1996;Moareﬁ et al., 1997).While the PxxPmotif seemed required
for disease progression in animal models (Khan et al., 1998) and
humans (Trible et al., 2007), the molecular role of Hck in the viral life
cycle remained unclear (Saksela, 2011). Hck is expressed predomi-
nantly in myeloid cells but not T cells, the main host cell of HIV. It was
therefore speculated that in T cells Nef may recruit another SH3
domain-containing protein; however, the identity of this protein is
still a matter of debate (Saksela, 2011).
In transient transfection systemsNef-inducedHck activation dysreg-
ulated signaling at the Golgi apparatus (Hassan et al., 2009; Hiyoshi
et al., 2012), consistent with reports suggesting that secretory mem-
brane trafﬁcking from the Golgi is regulated by Src kinases (Sallese
et al., 2009). In line with such a function, Hck augmented productionur).
. This is an open access article underand release of pro-inﬂammatory cytokines like TNF (English et al.,
1993; Ernst et al., 2002). ProTNF is processed also in Golgi-derived com-
partments after PMA stimulation or Nef-induced ADAM17 activation,
and is secreted in vesicles via membrane protrusions (Ostalecki et al.,
2016). Such protrusions were also observed following Hck activation
(Carreno et al., 2002).
A number of reports demonstrated HIV replication in liver cells
in vitro and in vivo (Blackard and Sherman, 2008; Cao et al., 1992,
1990; Housset et al., 1993; Tuyama et al., 2010) and HIV infection is fre-
quently associated with liver disorders (Mendeni et al., 2011; Price
et al., 2012). HIV-induced immunosuppression and the risk of liver-
related death correlate strongly, and liver-related morbidity is the
most frequent cause of death in chronic infection (Towner et al., 2012;
Weber et al., 2006). At present, however, HIV liver infection is not con-
sidered to be relevant for disease pathogenesis.
We recently reported that the number of ADAM17/Nef-containing
plasma extracellular vesicles (pEV or HIV pEV) is strongly upregulated
in HIV infection. Their number did not decline during therapy and
their ADAM17/Nef content correlated inversely with CD4 T cell counts.
Hence identifying the compartment shedding HIV pEVwas of consider-
able importance. Preliminary ﬁndings had suggested that they did not
derive from T cells (Lee et al., 2016). In this report we aimed at identify-
ing their cellular origin, analyzing the factor content in HIV pEV. Thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in HIV biology, but also pointed at myeloid cells and hepatocytes as the
likely cellular origin of HIV pEV.2. Materials and Methods
2.1. Cell Lines
Liver cell lines Huh7 and Sk-Hep-1 (kindly provided by P. Knolle,
Technische Universität München) were grown in DMEM (Sigma-Al-
drich) supplemented with 10% Fetal calf serum (FCS, Sigma-Aldrich)
and 1% penicillin-streptomycin (Lonza). Sk-Hep1 cells were addition-
ally maintained in 40 μM β-mercaptoethanol (Carl Roth). LX-2 cells
were provided by SL. Friedman (Icahn School of Medicine) and cultured
in DMEM high glucose (Life Technologies) supplemented with 2% FCS,
1% penicillin-streptomycin. All cells were grown at 37 °C under 5% CO2.2.2. EV Depletion of FCS and Human Serum for Cell Culture
To assure that EV generated from cell culturewere not contaminated
by outside sources, heat inactivated FCS and human serum for medium
supplementation were depleted of bovine EV by ultracentrifugation for
18 h at 110,000g, 4 °C before use.2.3. Isolation and Puriﬁcation of EV
EV puriﬁcation was performed essentially as described previously
(Lee et al., 2016). Brieﬂy, supernatants were collected after 48 h and
centrifuged for 20 min at 2000g, 30 min at 10,000g and ultra-
centrifuged for 1 h at 100,000g. Pellets were resuspended in 35 ml PBS
and centrifuged at 100,000g for 1 h. Pellets were resuspended in 100 μl
PBS and considered as EV preparations.
For EV puriﬁcation frompatient samples, 30ml blood plasmawas di-
luted with 30 ml PBS and centrifuged for 30 min at 2000g, 45 min at
12000g and ultra-centrifuged for 2 h at 110,000g. Pellets were resus-
pended in 30 ml PBS and centrifuged at 110,000g for 1 h. Pellets were
again resuspended in 100 μl PBS and considered as EV preparations.
For further puriﬁcation, EV were diluted in 2 ml of 2.5 M sucrose,
20mMHepes/NaOH, pH 7.4 and a linear sucrose gradient (2–0,25M su-
crose, 20mMHepes/NaOHpH7.4)was layered on top of the EV suspen-
sion. The samples were then centrifuged at 210,000g for 15 h. Gradient
fractions were collected and the refractive index was determined. Each
fraction was diluted in 10 ml PBS and ultra-centrifuged for 1 h at
110,000g. Pellets were solubilized in SDS sample buffer or resuspended
in 100 μl PBS and analyzed by immunoblotting or Cytokine/Chemokine/
soluble Factor (CCF) protein array (see Supplementary information).
To validate our centrifugation-based pEV isolation protocol, we gen-
erated an EV spike-in control (from a stable cell line producing EV), con-
taining an EBV-derived miRNA (BHRF1-2*) that was not found in
human pEV-miRNAs, but was detectable by the miRNA microarray
(Agilent). After spike-in, BHRF1-2* miRNA was readily detected with
comparable efﬁciency in 4 different plasma samples (data not shown).2.4. Peripheral Blood Mononuclear Cell (PBMC) Preparation
Leukoreduction system chambers (LRSCs) (Pfeiffer et al., 2013) from
healthy donors were acquired after plateletpheresis. The resulting
platelet free cell samplewas diluted 1:2 in PBS and the PBMC containing
buffy coat was isolated after density gradient centrifugation on
Lymphoprep (Axix Shield 1114544) at 500g for 30min at room temper-
ature. PBMCs were then washed 3 times in PBS/1 mM EDTA; 1. wash:
282 g, 15 min, 4 °C; 2. wash: 190 g, 10 min, 4 °C; 3. wash: 115 g,
12 min, 4 °C.2.5. Generation of Immature/Mature Dendritic Cells (DC)
PBMCswere isolated from LRSCs as described above, resuspended in
1× BD IMag Buffer (BD Biosciences 552362) and counted. Monocytes
were then isolated from 1.5 × 107 PBMCs using BD IMag Anti-Human
CD14 Magnetic Particles (BD Biosciences 557769) according to the
manufacturer's instructions. 6.0 × 106 monocytes per well were then
seeded in a 6 well plate in RPMI supplementedwith 1% heat inactivated
human serum from human male AB plasma (Sigma-Aldrich).
Monocyte-derived DC were generated supplementing the medium
with 800 IU/ml of recombinant GM-CSF and 250 IU/ml of recombinant
IL-4 (both from CellGenix) on day 1 after isolation and 400 IU/ml of re-
combinant GM-CSF and 250 IU/ml of recombinant IL-4 on days 3, 5 and
6. For EV isolation from immature DC, cells were washed with PBS on
day 7 and 10 ml RPMI containing 1% of EV-depleted, heat-inactivated
human serum and 1% of penicillin/streptomycin was added. After 24 h
the supernatant was harvested. For EV isolation frommature DC, imma-
ture DC cultureswere supplemented for 24 hwith amaturation cocktail
200 IU/ml IL-1ß, 1000 IU/ml IL-6 (both from CellGenix), 10 ng/ml TNF
(beromun; Boehringer Ingelheim) and 1 μg ml−1 Prostin E2 (PGE2,
Pﬁzer). Subsequently cells were washed 1 time with PBS and seeded
in 10 ml of RPMI supplemented with 1% of heat-inactivated and EV-
depleted serum and 1% of penicillin/streptomycin. After additional
24 h the supernatant was harvested. EV from immature and mature
DC were puriﬁed as described above.
2.6. Generation of Macrophages
PBMCs were isolated from LRSCs as described above. Monocytes
were separated from the non-adherent fraction (NAF) by plastic adher-
ence on cell culture ﬂasks and cultured in RPMI supplemented with 1%
human serum and 1% of penicillin/streptomycin. On days 1, 3, 5, 7 and 9
after seeding, medium was supplemented with 800 IU/ml of GM-CSF.
On day 11, medium was removed, cells were washed with PBS and
20 ml of RPMI supplemented with 1% of EV depleted human serum
and 1% of penicillin/streptomycin was added. After 24 h supernatant
was harvested and EV were isolated as described above.
2.7. Generation of Primary Myeloid Cells (Adherent PBMC)
PBMCs were isolated from LRSCs as described above. Monocytes
were separated from the non-adherent fraction (NAF) by plastic adher-
ence on cell culture ﬂasks and cultured in RPMI supplemented with 1%
human serum and 1% of penicillin/streptomycin. On day 1 after seeding,
medium was supplemented with 800 IU/ml of recombinant GM-CSF
and 250 IU/ml of recombinant IL-4 (both from CellGenix). After 24 h su-
pernatant was harvested and EV were isolated as described above.
2.8. Nef Antibodies and Detection Reagents
Different anti-Nef antibodies and reagents were used: (1) anti-Nef
JR6, a mouse monoclonal antibody (Abcam ab42358); (2) anti-Nef
2A3, a mouse monoclonal antibody (Abcam ab77172); (3 and 4) anti-
Nef sheep serum, either as a puriﬁed biotinylated polyclonal antibody
or non-labeled (both from Targeted Afﬁnity Oy, Helsinki); (5) anti-Nef
polyclonal serum (provided by Mark Harris, Leed University). All Nef-
antibodies were used to demonstrate the presence of Nef in pEV. For
immunoblotting JR6 turned out to have the highest sensitivity and spec-
iﬁcity as judged by the ratio of Nef vs. background staining. For detec-
tion in tissue we used the biotinylated anti-Nef sheep serum and the
JR6 antibody.
2.9. Antibodies
The following antibodies were used for immunostaining or immu-
noblotting: anti-ADAM10 (mouse monoclonal, Abcam ab73402), anti-
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ADAM17 (rabbit polyclonal, Cell Signaling 3976), anti-HCK (rabbit poly-
clonal, Santa Cruz, sc-72), anti-Gag p24 (mouse monoclonal, Abcam
ab9071), anti-Gag p24 (mouse monoclonal, Abcam ab9044), anti-
CD63 (mouse monoclonal, BD Biosciences 556019), anti-CD81 (mouse
monoclonal, BD Biosciences 555675), anti-Tsg101 (mouse monoclonal,
Santa Cruz Cruz sc-7964), anti-Vpu (rabbit polyclonal, Biozol FBX-VPU-
101AP-100), anti-Vpr (rabbit polyclonal, NIH, provided by U. Schubert),
anti-phopho Src (rabbit polyclonal, Cell signaling 2101), anti-Vinculin
(rabbit polyclonal, Millipore AB6039), anti-Erk1/2 (rabbit polyclonal,
Cell signaling 4695), anti-Fyn (rabbit polyclonal, Genetex 109428)
anti-c-Yes (rabbit polyclonal, Genetex 100616), anti- Fgr (rabbit poly-
clonal, Genetex 102947), anti-Blk (rabbit polyclonal, Genetex 111546),
anti-Lck (mouse monoclonal, Santa cruz sc-433), anti-Lyn (rabbit poly-
clonal, Cell signaling 2732), anti-β-actin (mouse monoclonal, Sigma-
Aldrich A5316), Propidium iodide (Genaxxon bioscience,
M3181.0010), DAPI (4′,6-diamidino-2-phenylindole, Biomol ABD-
17510).
Primary antibodies were used at 1–2 μg ml−1 for immunoblotting, 2
μg ml−1 for immunoﬂuorescence and 5–10 μg ml−1 for FACS analysis.
The following secondary antibodies were used: Alexa Fluor 488 goat
anti-mouse and Alexa Fluor 555 goat anti-rabbit IgG (both from Life
Technologies) and anti-mouse IgG-Biotin conjugate and anti-rabbit
IgG-Biotin conjugate (LSAB+, Dako REAL Detection Systems, HRP/
AEC, Rabbit).
2.10. DNA Constructs, Transfections and Protein Assays
Expression plasmids for Nef and Nef-cofactors (hnRNPK, PKCδ, Lck)
were described previously (Lee et al., 2013). The HIV-Δenv (pNL-
4.3Δenv (Clavel et al., 1989)) expression plasmid was kindly provided
by U. Schubert (Department of Virology, University of Erlangen). Hck
expression plasmidswere kindly provided byKalle Saksela. The p59 iso-
form of humanHckwas providedwith a Kozak consensus sequence and
a kinase-inactive (K269N) derivative or an activated version lacking the
C-terminal inhibitory tyrosine phosphorylation site (Y501F) was gener-
ated by PCR mutagenesis. The constructs were inserted into the pEBB-
PP expression vector as BamHI-NotI (K269N) or BamHI-KpnI (Y501F)
fragments. In the latter case this creates an in-frame fusion with a 123
aa biotin acceptor domain from Propionibacterium shermanii
transcarboxylase. The GFP-proTNF-RFP fusion protein was described
previously (Lee et al., 2013). For immunoblotting experiments, plasmids
were transfected with Lipofectamine® LTX with Plus™ Reagent
(Invitrogen) according to the manufacturer's instructions, or using the
classical calcium phosphate procedure. Cells were analyzed 24–72 h
after transfection. Immunoprecipitations were performed as described
previously (Lee et al., 2013). In general 20 μg of cellular protein lysate
and 10 μg of EV lysate were loaded per lane. The latter corresponded
to the secretion from 2 to 4 mio Huh7 cells within 48 h.
2.11. Human Cytokine/Chemokine/Soluble Factor (CCF) Array
Puriﬁed EV from sucrose gradient fractions corresponding to equal
volume of cellular supernatant (in general 60 ml from 10 mio.
Transfected cells) or equal plasma volume were applied to the RayBio
Human Cytokine Array C-S (Hölzel Diagnostika, AAH-CYT-1000-2) ac-
cording to themanufacturer's instructions. Aminimum of 20 μg EV pro-
teins was used per ﬁlter incubation (see Supplement table S1).
2.12. ADAM17/α-Secretase Acitivity Assay
The assay was performed essentially as described previously (Lee
et al., 2016) using a commercial, SensoLyte®520 α-Secretase Activity
Assay Kit (AnaSpec 72085), according to the manufacturer's instruc-
tions. Brieﬂy, we placed sucrose gradient puriﬁed pEV (the equivalent
of 1 ml plasma) on a 96-well, black, ﬂat bottom plate (Greiner655900) and added a 5-FAM (ﬂuorophore) and QXL™ 520 (quencher)
labeled FRET peptide substrate for continuous measurement of enzyme
activity. Upon cleavage of the FRET peptide by the active enzyme, the
ﬂuorescence of 5-FAM is recovered and continuouslymonitored at exci-
tation/emission = 490 nm/520 nm by a preheated (37 °C) TECAN inﬁ-
nite M200 Pro plate reader.
2.13. Patient Material
Patient material was obtained from patients of the HIV clinic
(headed by T. Harrer) at the Department of Medicine 3, University Hos-
pital Erlangen. Plasmawas drawn from patients after informed consent.
At the time of sampling, non-viremic HIV patients were under ART for
prolonged periods without detectable viral load. None of the patients
had an active HBV or HCV virus infection at the time of blood - or tissue
sampling (see also Supplement table S2). CD4 and CD8 counts (cells/μl
blood) were determined by the Department of Medicine 3. In general,
6–7 ml of plasma was obtained from each individual per visit. Liver
FFPE tissue samples were obtained from 3 non-viremic clinically
healthy individuals under ART (see Supplement table S2). HIV spleen
tissuewas obtained fromanon-viremicHIV-infected individual after re-
section for a non HIV-related condition. Skin tissue was obtained from
two non-viremic individuals who had punch biopsies because of non-
HIV-related skin conditions. A fourth liver sample and gut tissuewas ob-
tained from a non-viremic individual who died shortly after admission
in 2015 due to liver failure (see Supplement table S2).
2.14. Immunostaining and Confocal Microscopy
For immunohistochemistry staining, FFPE samples were
deparafﬁnized and antigen retrieval was achieved in Tris-EDTA buffer
pH 9 at 100 °C for 30 min. For antigen detection the LSAB method
(Dako REAL Detection Systems) was used, performed by the Dako
Autostainer Plus.
For ICC analyses, transfected cells were cultured on glass slides for
2 h at 37 °C and subsequently ﬁxed by 3% PFA for 30 min at room tem-
perature followed by three washes with PBS/1% BSA. Cells were then
permeabilized with 0.1% Triton X-100/1% BSA and immunostained by
standard procedures (primary and secondary antibodies). Finally, the
cells were washed 30 min with PBS/1% BSA and mounted with
Fluoromount-G (SouthernBiotech). Slides were analyzed on a Zeiss
Laser Scanning Microscope LSM780 equipped with the ZEN software
(Carl Zeiss AG, Oberkochen, Germany).
For confocal microscopy analyses,ﬁxed sampleswere imagedwith a
laser scanning confocal microscope (LSM780; Carl Zeiss AG,
Oberkochen, Germany) equipped with a 63× objective. For Alexa488
the illumination was set at 488 nm and emissions were collected be-
tween 506 and 583 nm. For Alexa555 the illumination was at 561 nm
and emission collected between 574 and 667 nm. Detecting DAPI, illu-
mination was set to 405 nm and emission collected between 410 and
495 nm.
2.15. Multi-Epitope Ligand Cartography (MELC) Technology
TheMELC technology and it application for SPPL3 and ADAM prote-
ase detection has been described recently (Schubert et al., 2006). Brieﬂy,
a slide with a tissue specimen was placed on an inverted wide-ﬁeld
ﬂuorescence microscope (Leica DM IRE2, Leica Microsystems, Wetzlar,
Germany; ×20 air lens; numerical aperture, 0.7) ﬁtted with ﬂuores-
cence ﬁlters for ﬂuorescein isothiocyanate and phycoerythrin.
Fluorochrome-conjugated antibodies and wash solutions were added
and removed robotically under temperature control, avoiding any dis-
placement of the sample and objective. The repetitive cyclic process of
this method includes the following steps: (a) ﬂuorescence tagging,
(b) washing, (c) imaging and (d) photo bleaching; phase-contrast and
ﬂuorescence images were recorded by a high-sensitivity cooled CCD
154 J.-H. Lee et al. / EBioMedicine 28 (2018) 151–161camera (Apogee KX4, Apogee Instruments, Roseville, CA; 2048 ×
2048 pixels; 2 × binning results in images of 1024 × 1024 pixels; ﬁnal
pixel size was 900 × 900 nm). Data acquisition was fully automated.
2.16. Transmission Electron Microscopy
The EV samplewas ﬁxed in 2% (w/v) paraformaldehyde in PBS at 4 °C
overnight. Fixed EV were spread on carbon-coated 400-square-mesh
copper grids (Electron Microscopy Sciences, Hatﬁeld, PA, USA). After
20 min of incubation grids were washed with PBS and post-ﬁxed with
2% glutaraldehyde (w/v) in PBS for 5 min. After a series of washing
steps using distilled water, gridswere incubated in a 3% aqueous solution
of uranyl acetate (pH 4.5) that had been ﬁltered through a 0.22 μm ﬁlter
for 5 min. Grids were dried at room temperature and examined with a
transmission electron microscope (Leo 912; Zeiss, Oberkochen,
Germany).
To analyze pEV and EV by electron microscopy, we have puriﬁed
these vesicles by different means, including iodixanol gradient
(Optiprep) and antibody-coupled bead isolation. In all cases the vesicles
appeared to have a similar structure and size as demonstrated in Sup-
plement Fig. 3C.
2.17. Immunoisolation of pEV/EV by Magnetic Beads
Antibodies were coupled to magnetic microbeads by a Miltenyi
Biotec (Bergisch Gladbach, Germany). For isolation of pEV, 2 ml blood
plasma was diluted with 2 ml PBS and 50 μl of antibody-coupled
beads were added for 1 h and subsequently subjected to magnetic
immunoisolation with MACS® Technology (Miltenyi Biotec) using MS
columns. To purify EV from cells, cell cultured supernatants were
collected and were puriﬁed by combining differential centrifugation
and column-based bead isolation. The vesicles were ﬁnally eluted with
45 μl of hot (95 °C) SDS sample buffer and all of the vesicle lysate was
subsequently analyzed by western blot. The column ﬂow-through was
collected and centrifuged at 110,000g (pEV) or 100,000g (EV from
cells) for 1 h. Pelletswere solubilized in SDS sample buffer and analyzed
by western blot.
2.18. DNA/RNA Extraction and PCR Ampliﬁcation
DNAextraction fromparafﬁn embedded liver tissues DNA extraction
was donewithNucleoSpin Tissue: Cat. No: 740952.250, according to the
manufacturer's instructions. Subsequently, whole genome ampliﬁca-
tion was performed via Degenerate Oligonucleotid-Primed PCR (DOP-
PCR) as previously described (Telenius et al., 1992). Reverse transcrip-
tion of extracted pEV RNAwas performed using the commercially avail-
able QantiTect Reverse Transcription kit (Qiagen, Cat. No: 205311).
For ampliﬁcation of HIV LTR and pol sequences, the following spe-
ciﬁc primers were used in nested PCRs: LTR, outer primers: 9148s
(sense) (CAA GGC TAC TTC CCT GAT TGG CA), 9148sG (CAA GGA TTC
TTC CCA GAT TGG CA), 9148sD (CAA GGC TTC TTC CCT GAT TGG CA)
9545as (antisense) (GAG ACC CAG TAC AGG CAA AAA GC), 9545asG
(GAG ACC CAG TAC AGG CGA GAA GC), 9545asA (GAG ACC CAG TAC
AGG CGA AAA GC). LTR, nested primers: 9172s (AAC TAC ACA CCA
GGG CCA GGG), 9172sA (AAT TAC ACA CCA GGG CCA GGG), 9172sC
(AAC TAC ACA CCG GGA CCA GGG), 9519as (TGC TTA TAT GCA GCA
TCT GAG GG), 9519asG (TGC TTA TAT GCA GCT TCT GAG GG).
Pol, outer primer: pol2249s (ATC ACT CTT TGG CAA CGA CC)
pol2589as (TGG CCA TCC ATT CCT GG). Pol, nested primers: pol2372s
(AAA AAT GAT AGG GGG AAT TGG), pol2557as (CTG GTA CAG TTC
AAT AGG AC).
The PCR was performed with the Peqlab PeqSTAR 2× thermocycler
system using AmpliTaq DNA polymerase and the included buffer (Ap-
plied Biosystems) according to the manufacturer's instructions. PCRs
were performed with the following cycling conditions: LTR outer and
nested: 95 °C 3′/95 °C 3′/60 °C 40″/72 °C 45″//95 °C 1′/60 °C 40″/72 °C45″ + 2″/cycle//×29/72 °C 5′/4 °C storage. Pol outer and nested: 95 °C
2′//95 °C 30″/52 °C 40″/72 °C 90″+1′/cycle//×30/72 °C 5′/4 °C storage.
PCR products were detected on a 1% agarose gel using the Amersham
Imager 600 system.
2.19. Statistical Analysis
GraphPad Prism andMicrosoft Excel software were used for statisti-
cal analysis. The standard deviation of the mean was calculated using
the Student's t-test.
3. Results
3.1. HIV pEV Contain Hck
In vitro, Nef-induced extracellular vesicles (EV) upload proteins
from lipid rafts (Lee et al., 2013). We therefore speculated that pEV
from patients may harbor a tyrosine kinase that could help to identify
their cellular source. Puriﬁed pEV from 8 non-viremic patients and 3
healthy controls were blotted for 7 tyrosine kinases. Hck was identiﬁed
in all HIV samples but not in controls (Supplement Fig. S1a and Fig. 1a,
red box). Only in one case (HIV.08) also Yes and Fyn were found
(Fig. 1a). In addition, a phopho-Src (p-Src) staining was detected, sug-
gesting that the pEV-associated tyrosine kinase was activated. Using
the HIV.08 plasma sample and a bead-coupled anti-αvβ5 antibody
that isolates HIV pEV (Lee et al., 2016), we found that Hck, but not
Yes, co-isolated with Nef and ADAM17 (Fig. 1b, red box). These results
suggested that Nef-induced Hck activation was potentially connected
to the generation and/or function of HIV pEV.
3.2. Nef-Induced Hck Activation Correlates With ADAM17 Activation and
Secretion
In view of its role in TNF secretion and Golgi signaling, we assumed
an involvement of Hck in ADAM17 activation, the sheddase of TNF, and/
or pEV-associated release. As expected, co-transfection of Hck with Nef
activated the tyrosine kinase, evidenced by a shift to a slower migrating
protein band (Fig. 1c, red box) and binding of the phospho-speciﬁc anti-
Src family antibody (Fig. 1d, red box). This effect correlatedwith the ap-
pearance of an activated form of ADAM17 (Fig. 1c, blue box), which we
previously observed only after co-expression of Nef and associated fac-
tors (Nef-associated kinase complex or NAKC; Fig. 1c, green boxes) (Lee
et al., 2013).
Nef transfection into Hck-expressing 293T cells (p59 stable transfec-
tion) induced the uploading of activated ADAM17 into EV (Fig. 1e, red
box). Conversely, a mutation in the Hck-interacting PxxP domain of
Nef (P76/78A: Nef.AxxA) abolished this effect (blue box). Taken to-
gether, Hck activation by Nef correlated with ADAM17 activation and
its pEV-associated release.
3.3. Myeloid Cells Require Hck for ADAM17 Activation and Secretion
We asked whether cells of the myeloid lineage, which express Hck,
require the tyrosine kinase for ADAM17 activation and/or EV release.
In mature DC (mDC), but not immature DC (iDC) (Supplement
Fig. S2a and b), a p-Src reactive and shifted Hck protein band was de-
tected, as well as activated ADAM17 and proTNF cleavage (Fig. 1f, red
box). These effects were abolished in the presence of a tyrosine kinase
inhibitor (PP2) (Fig. 1g, red box). An introduction of Nef into iDC in-
duced ADAM17 activation and proTNF cleavage, while Jurkat T cells
were non-responsive and contained no proTNF (Fig. 1h, compare red
and blue box). In the same Nef-transfected iDC lysates an activation of
Hck was veriﬁed, evidenced by protein band shift and p-Src reactivity
(Fig. 1j, red box). Extracellular vesicles (EV) puriﬁed from Nef-
transfected, but not vector-transfected iDC culture supernatants
contained activated ADAM17 (Fig. 1k, red box), similar as EV from
Fig. 1.Hck is required for extracellular vesicle (EV)-associated secretion of ADAM17. (a–b) Hck is present in HIV pEV. (A) Blotting of Hck and indicated tyrosine kinases in pEV puriﬁed by
differential centrifugation (from 2ml plasma) from 2 non-viremic HIV patients (HIV.07/0.08) and one healthy control (cont.02). For blotting control the tyrosine kinases were transiently
expressed in 293T cells. (b) Blotting of Hck, Yes andNef in pEV fromHIV.08 and a healthy donor (cont.03) isolated by anti-αvβ3-coupledmagnetic beads. For blotting control lysates from
NIH3T3 and 293T cells transfectedwith ADAM17 and Nef were used. Beads: bead-isolated pEV; FT: ﬂow through. (c–e) Nef-activated Hck correlates with ADAM17 activation. (c) Blotting
of indicated factors in lysates of transiently transfected 293T cells. NAKC:Nef-associated kinase complex (hnRNPK, Lck, PKCδ). (d) Immunoprecipitation ofHck from transiently transfected
293T cells as indicated, and blotting for p-Src. (e) Blotting of indicated factors in lysates of 293T cells stably expressing (stbl. exp.) p59 Hck, and transiently transfected (trans. transf.) as
indicated (lower four panels). EV puriﬁed from the supernatants were blotted for ADAM17 and Tsg101 (upper two panels). (f–m) EV-associated ADAM17 secretion from myeloid cells
requires Hck. (f) Blotting of indicated factors in lysates of immature and mature dendritic cells (iDC/mDC). (g) Blotting of indicated factors in lysates of iDC and mDC, treated/not
treated with the tyrosine kinase inhibitor PP2. (h) Blotting of indicated factors in lysates of iDC, mDC, Jurkat and 293T cells, transiently transfected as indicated, or untreated (mDC).
(j) Immunoprecipitation of Hck from Nef-transfected iDC and mDC and blotting for indicated factors. (k) Same experiment as shown in (H), blotting EV puriﬁed from culture
supernatants for indicated factors. (l) Blotting of indicated factors in lysates of Nef-transfected macrophages. (m) Same experiment as shown in (l), blotting EV puriﬁed from culture
supernatants. Colored boxes in all panels depict results that are described in the text.
155J.-H. Lee et al. / EBioMedicine 28 (2018) 151–161mDC without Nef transfection (blue box). No ADAM17 was found in
Jurkat-derived EV (green box).
Similar observations were made in primary macrophages (Supple-
ment Fig. S2c). Transfection of Nef activated ADAM17 (Fig. 1l, red box)
and lead to the secretion of ADAM17-containig EV (Fig. 1m, red box),although the EV secretion activity of macrophages was rather low as
judged by the (volume-adjusted) EV protein abundance from 293T
cells andmacrophages. Taken together, in DC andmacrophages Hck ac-
tivation correlatedwith ADAM17 activation and secretion, and the pres-
ence of Nef induced this mechanism.
156 J.-H. Lee et al. / EBioMedicine 28 (2018) 151–1613.4. HIV pEV Marker Proﬁles Implicate Hepatocytes as Their Cellular Source
To identify a putative myeloid compartment shedding HIV pEV, we
compared the cytokine, chemokine and soluble factor (CCF) proﬁle of
EV secreted by primary myeloid cells from infected individuals with
that from HIV pEV, which we described recently (Lee et al., 2016). Plas-
tic adherent PBMC (mostly monocytes and iDC) from 5 non-viremic in-
dividuals cultured in vitro (72 h) secreted EVwith a CCF pattern lacking
almost all the factors found in HIV pEV (Fig. 2a, red box). Hence it
seemed unlikely that HIV pEV derived from peripheral myeloid cells.
We noticed that the CCF content of HIV pEV contained many
hepatocyte-typical inﬂammatory factors (Rowell et al., 1997), or factors
predominantly secreted by liver cells (e.g. IGFBP-1 and 3 (Arany et al.,
1994) and IL6-R (Desgeorges et al., 1997)) (Fig. 2a and (Lee et al.,
2016)). We therefore compared the CCF proﬁles of EV derived from
Huh7 and SK-Hep1 cells transfected with HIVΔenv or vector control.
While vector-transfected cells produced EV with BDNF only, HIVΔenv-
transfected cells secreted EV containing 20 different CCF, of which 15
matched those in HIV pEV (Fig. 2b, black boxes). For control, 293 T
cells were transfectedwith HIVΔenv and produced EVwith a greatly re-
duced CCF pattern. Together these result supported the assumption that
liver cells were one possible source of HIV pEV.
3.5. HIV pEV Contain Liver-Typical Factors
For further clariﬁcation, we screened lysates of HIV pEV for liver-
typical factors.We detected haptoglobin, an acute phase proteinmainly
secreted by liver cells (Yang et al., 2013). The factor was found in su-
crose gradient fractions along with activated Hck and Nef (Fig. 3a, red
box), but not in respective fractions of controls. Using anti-αvβ5
coupled beads, haptoglobin was co-isolated with ADAM17 and Nef
from HIV pEV of 2 non-viremic patients with high and low CD4 count
(Fig. 3b). Haptoglobin correlated in abundance with Nef (red boxes)
and was not found in the ﬂow through. Resting Huh7 cells did not ex-
press haptoglobin, however expression was induced after transfection
of the HIVΔenv construct (Fig. 3c, red box). In addition, haptoglobin
was then found in EV puriﬁed from these supernatants (blue box).
Next we compared receptor surface pattern and morphology of HIV
pEVwith that of liver cell-derived EV. Anti-αvβ5 bead-isolated HIV pEV
contain ADAM17, Vpu, Nef (Fig. 3d, red box) and lack Tsg101 and CD81Fig. 2.Marker proﬁles imply hepatocytes as a possible source of HIV pEV. (a) Protein array
(RayBiotech) analyzing the content of cytokines, chemokines and soluble factors (CCF) in
EV secreted by primary myeloid cells (PMC EV: plastic-adherent PBMC) from 5 infected
non-viremic individuals and 5 healthy donors, cultured for 72 h (cultured separately,
pooled for analysis). For comparison HIV pEV (15 ml plasma) from one non-viremic HIV
patient was assessed as described recently 24. (b) CCF protein array analysis as in (B).
EV were puriﬁed from 2 liver lines (Huh7, SkHep-1), and 293T cells. The cells were
transfected for 72 h with a HIVΔenv construct or vector control (expression control in
Supplement Fig. 4b). Assay input details are summarized in Supplement table S1.
Colored boxes in panels depict results that are described in the text.(green boxes) (Lee et al., 2016). The latter discriminates them from clas-
sical multivesicular body (MVB)-derived exosomes. Electron micro-
graphs supported this conclusion, revealing vesicles of 100–150 nm
size, composed of a membranous coat and a spherical core, structures
not described for exosomes (Thery et al., 2009) (Fig. 3h). Notably, pEV
puriﬁed by iodixanol gradient (Optiprep®) from cancer patients had a
similar appearance, structure and size as HIV pEV, indicating that this
type of vesiclemay develop not only in the course of HIV infection (Sup-
plement Fig. S3a).
Anti-αvβ5-isolated EV from HIVΔenv-transfected Huh7 cells had
the same protein proﬁle (Fig. 3e, red and green boxes) and identical
shape, structure and size as HIV pEV (Fig. 3h). Notably, EV with similar
appearance, structure and size were also secreted by HIV-transfected
293T cells and mature dendritic cells (puriﬁcation by Optiprep® gradi-
ent; Supplement Fig. 3a). The latter have, like HIV EV and pEV, a rich
content of effector molecules (see below Fig. 3, and data not shown).
Hence, the EV secretion induced by HIV is not speciﬁc for Huh7
hepatocytes.
Sk-Hep1-derived EV gave a comparable proﬁle (Fig. 3f), but lacked
activated ADAM17 (red box). Bead-isolated EV from HIVΔenv-
transfected Jurkat cells did not harbor Nef or ADAM17, but Tsg101 and
CD81. Instead, Nef was found in the ﬂow through. In addition, Vpu
was not uploaded into EV, although it was present in the cell lysate
(Fig. 3g; expression control in Supplement Fig. S4a). These data sug-
gested that hepatocyte-derived EV matched the protein proﬁle and
morphological appearance of HIV pEV.3.6. HIV Liver Tissue Expresses Hck, SPPL3 and Viral Gene Products
In healthy liver Hck is present only in bile duct cells (www.
proteinatlas.org/). Also the hepatocyte-like Huh7 and liver sinus endo-
thelial cells (SkHep1) revealed only low Hck abundance; however,
transfection of HIVΔenv upregulated Hck protein levels in both cell
types. In addition, Hck was activated in Huh7 cells as demonstrated by
p-Src staining and protein band shift (Supplement Fig. S3b). In line
with this result, ADAM17 was activated and secreted in/by Huh7 but
not in/by SkHep1 cells (Supplement Fig. S3c).
We analyzed liver tissue from aHIV-infected non-viremic individual
who died of liver cirrhosis-associated complications (Supplement table
S2). Almost all hepatocytes stained strongly for Hck, while in a liver
sample from a healthy control only spindle-shaped endothelial cells
gave positive signals (Fig. 4a, images 1). For control, gut tissue of the pa-
tient was stained for Hck, but no difference was recorded in comparison
to the control (images 2).
ADAM17 (data not shown) and ADAM10 expression did not differ in
liver tissues frompatient and control (Fig. 4a, images 3). Thuswe looked
for alternative evidence suggesting ADAM protease activation. We re-
cently described that the expression of the endopeptidase SPPL3 acti-
vates ADAM10 (Ostalecki et al., 2017). This protease is also activated
by HIV and shuttled into EV (Supplement Fig. S3c, and (Lee et al.,
2016)). In healthy liver tissue, spindle-shaped cells, but not hepatocytes,
expressed SPPL3. Conversely, in the liver tissue a prominent staining of
SPPL3 was found in hepatocytes predominantly in a perinuclear com-
partment (images 4, see inserts). To determine whether these effects
could have been caused by Nef, we stained the tissue with different
Nef antibodies. Most but not all hepatocytes gave a signal for Nef (im-
ages 5, upper panels). Using the Nef JR6 antibody, we found that the
viral protein, like SPPL3, localized to a perinuclear compartment (im-
ages 5, lower panels). No staining for Nef was seen with control tissue.
For conﬁrmation we transfected Huh7 hepatocytes with HIVΔenv
and analyzed the cells for co-expression of Hck, SPPL3, ADAM17 and
viral proteins using the MELC technology (Ostalecki et al., 2017). This
technology allows the assessment of multiple proteins in one cell
layer. The results conﬁrmed that protein abundance and colocalization
of Hck, SPPL3 and ADAM17 increased notably in the presence of Nef
Fig. 3.HIV pEV contain liver-typical factors. (a–b) Presence of haptoglobin in HIV pEV. (a)Western blot analysis of pEV puriﬁed by sucrose gradient from a non-viremic HIV patient (non-
vir. HIV) and a healthy control. The individual fractionswere blotted for indicated factors including haptoglobin (red box). Lys.: lysates of transfected 293T cells serving as positive control.
(b) HIV pEV isolation from plasma of 2 non-viremic patients with a high and low CD4 count using anti-αvβ3-coupled magnetic beads. Bead isolated pEV (bead) and ﬂow through (FT)
were analyzed for the indicated markers. (c) Lysates of Huh7 cells transfected with HIVΔenv or vector (vec.), and EV derived from these cells were blotted for markers as indicated.
Nef-transfected HeLa cells that express haptoglobin served as positive control. (d–g) HIV pEV and Huh7-derived marker proﬁles and morphology are identical. (d) Blotting of anti-
αvβ3 antibody-isolated HIV pEV from one non-viremic patient. Bead isolated pEV (bead) and ﬂow through (FT) were analyzed for the indicated markers. (e–g) Same experimental set
up as in (d); however, EV were obtained from different cell culture supernatants as indicated. Cells were either transfected for 72 h with a HIVΔenv viral construct (HIV) (expression
control in Supplement Fig. S4a) or an empty vector (vc.). (h) Electron micrographs of anti-αvβ3 antibody-isolated HIV pEV and Huh7-derived EV that were transfected with HIVΔenv.
Colored boxes in all panels depict results described in the text.
157J.-H. Lee et al. / EBioMedicine 28 (2018) 151–161andVpu (Fig. 4b). Thus it seemed plausible that HIV infection of liver tis-
sue induced Hck expression and ADAM protease activation.
Our ﬁndings in this liver tissue sample could have been the conse-
quence of the advanced stage of the chronic infection and/or the liver
cirrhosis. We therefore analyzed FFPE (formalin ﬁxed parafﬁn embed-
ded) liver biopsy sections from 3 non-viremic HIV patients(Supplement table S2) and healthy controls. About 25% of liver cells
fromone infected individual gave aNef-speciﬁc staining (Fig. 4c, left im-
ages; summary in Supplement table S3). The result was conﬁrmed by
staining of a second - (Fig. 4c, right images) and a third liver tissue sam-
ple (data not shown). Nef expression was accentuated in endothelial
cells (Fig. 4c, inserts 1, 2). However, hepatocytes were the predominant
Fig. 4. Overexpression of Hck, SPPL3 and Nef in HIV liver tissue. (a) Immunohistochemistry analysis of liver and gut tissue sections (fresh frozen tissue) from a non-viremic HIV patient
(P04, see Supplement table S2), and two healthy individuals. Different sections were stained by different cellular markers and Nef as indicated. To demonstrate Nef subcellular
localization one section was stained with a second anti-Nef antibody (JR6). Inserts serve to magnify cells (images 1 and 4). Arrows in images 5 indicate cells positive or negative for
Nef. (b) Analysis of HIVΔenv-transfected Huh7 cells by multi-epitope-ligand-cartography (MELC). Huh7 cells were transfected with HIVΔenv and 48 h later analyzed by MELC-
technology 30 for the co-expression of the indicated proteins. A17: ADAM17; Vim.: Vimentin. (c) Immunohistochemistry analysis of Nef expression in two FFPE liver sections
(biopsies) from non-viremic HIV patients (P03 and P04, see Supplement table S2) under ART and two healthy individuals. (d) Nef expression in spleen, skin and lymph node (fresh
frozen tissue). Boxes depict areas that were magniﬁed. * Non-speciﬁc staining of epidermal melanin. Quantiﬁcation of positive cells in (A, C and D) is shown in Supplement table S3.
158 J.-H. Lee et al. / EBioMedicine 28 (2018) 151–161Nef-expressing cell population (Fig. 4c, insert 3). For comparison, other
organ tissue sections from different non-viremic HIV patients were
stained for Nef and positive results were found in spleen (1.7% of all
cells), skin (0.8%) and in a lymph node (4.5%) (Fig. 4c, summary in Sup-
plement table S3). Thus Nef was expressed in hepatocytes.3.7. Expression of Gag p24 in HIV Liver Tissue
The expression of Nef implied that liver cells were infected byHIV as
suggested previously (Cao et al., 1992; Housset et al., 1993). The liver
sample described in Fig. 4a and all three liver biopsies were stained
159J.-H. Lee et al. / EBioMedicine 28 (2018) 151–161for p24. The results revealed a demarcated staining, predominantly in
hepatocytes (Fig. 5a and b; third biopsy not shown). Quantiﬁcation of
p24 in one biopsy revealed 18% p24-positive cells (Supplement table
S3).
For conﬁrmation, DNA was extracted from two tissue samples, am-
pliﬁed by DOP PCR and subjected to a second PCR using HIV pol- and
LTR- speciﬁc primers. Both biopsy samples gave a positive reaction
with both probes (Fig. 5c). When RNA from gradient-puriﬁed HIV pEV
was analyzed for HIV transcripts, only LTR- but not pol-ampliﬁcations
were readily detected after nested PCR. A limiting dilution revealed pos-
itive PCR signals from as few as 30 μl of pEV plasma equivalent (Fig. 5d).
The resultswere consistentwith a previous publication discovering TAR
RNA in EV from infected individuals (Narayanan et al., 2013).
In light of these results we speculated that non-infectious Gag parti-
cles could be secreted by the liver. Plasma EV were pelleted from 10 ml
of a non-viremic plasma sample and 1.5 ml pEV plasma equivalents
were analyzed by dot blot. After prolonged membrane exposure, a
faint p24 signal was detected (Fig. 5e, red box). Since we did not detect
Gag p24 in HIV pEV (Lee et al., 2016) and since in chronic infection in-
fected T cells release no or only few virus particles, this Gag p24 could
have originated from a different reservoir, as for example infected
liver cells. In summary all our results are consistent with the conclusion
that HIV pEV were secreted at least in part by infected liver cells.
4. Discussion
Weprovide evidence that hepatocytes at least contribute to HIV pEV
secretion. Relevant for this conclusion were the detection of liver-
typical factors in bead-isolated HIV pEV, and the demonstration of
viral proteins and Hck expression in liver tissue. It is possible that tissue
myeloid cells, e.g. macrophages or kupfer cells, also secrete HIV pEV.
However, since the EV secretion activity was low in macrophages
(Fig. 1m) and the CCF proﬁle from peripheral monocytes/iDC differedFig. 5.HIV infection of the liver. (a–b) Immunohistochemistry analysis of Gag p24 in liver biopsi
of Patient P01 and P02. Boxed areas were magniﬁed (images 1–3). Quantiﬁcation of positive ce
P04) shown in Fig. 4A and in a healthy control. Box and arrows indicate cells positive and nega
round PCR ampliﬁcation of HIV pol and LTR segments using extracted genomic DNA from liver
pol and LTR segments using reverse transcribed RNA from gradient-puriﬁed pEV as templates. In
plasmavolumes (right panel). (e) Detection of Gag p24 in plasma of non-viremic patients. Plasm
ultracentrifugated overnight. The pellet was resuspended in PBS and 1.5 ml plasma equivalentconsiderably from that of HIV pEV (Fig. 2b), we assume that myeloid
cells may have only a minor role in maintaining the high plasma con-
centration levels of pEV.
We further demonstrate that Hck and Nef are linked to a particular
secretion mechanism, potentially required for the release of pro-
inﬂammatory EV. The biological relevance of HIV pEV is not entirely
clear. Based on results in this and our previous report we would specu-
late that they stimulate the resting T cell compartment as implied by re-
cent results (Arenaccio et al., 2014, 2015). By side effect HIV pEV may
contribute to HIV comorbidities and altered immunological parameters
in chronic infection, for example through ingestion by monocytes (Lee
et al., 2016).
We describe that HIV pEV, aside from lacking the exosome markers
CD81 and Tsg101, have a two-layered composition, possibly a plasma
membrane coat and a spherical core. This structure seems more com-
plex than described for exosomes, which are generated by invagination
of endosomal membranes into multivesicular body (MVB) (Thery et al.,
2009). While this observation requires further ultrastructural analysis
and conformation, itwould support our assumption that HIV pEV are in-
duced de novo by the activation of a speciﬁc secretion mechanism. We
termed this mechanism vesicular or endosomal secretion; however, it
could represent a variant of a non-conventional secretion mechanism
(Nickel and Rabouille, 2009). In line with a role of Hck in pro-
inﬂammatory factor release, cytoskeleton reorganization and plasma
membrane conﬁguration (Poh et al., 2015; Saksela, 2011), our results
imply that the kinase is required to induce this secretion form. An im-
portant effector in this context could be dynamin-2 (Weller et al.,
2010), interestingly a Nef-interacting molecule (Pizzato et al., 2007)
that is directly involved in the formation of vesicles from the Golgi
(Kessels et al., 2006).
Although independent laboratories, including ours, came to the con-
clusion that liver cells are infected in patients (Cao et al., 1992; Housset
et al., 1993), liver infection is not considered to be relevant for HIVes and tissue sample described in Fig. 4A and B. (a) Staining of p24 in the FFPE liver biopsies
lls (in %) is shown in Supplement table S3. (b) Staining of p24 in the liver sample (patient
tive for p24. (c–d) HIV DNA/RNA analysis by PCR in tissue and non-viremic pEV. (c) Two-
samples shown above, applying a DOP ampliﬁcation step. (d) Nested PCR ampliﬁcation of
cluded is a limiting dilution analysis using template amounts that correspond to indicated
a (10ml) froma healthy control and a non-viremic, lowCD4 patient (98 CD4 cells/μl)were
s were blotted as indicated (dot blot technique). The red box depicts the p24 signal.
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tion. First, the viral entry mechanism into liver cells is not clear,
although several groups described a CD4-independent mechanism
that seemingly involves HIV co-receptors including CXCR4, CCR5 and a
DC-SIGN-like protein (Bashirova et al., 2001; Cao et al., 1990; Iser
et al., 2010). Second, replication in liver cells, like in DC or monocytes,
appears to be too inefﬁcient (Kong et al., 2012) to have a relevant role
in pathogenesis. Indeed, we observed no correlation between viral
copy number or p24 plasma levels in viremic patients and Nef abun-
dance in HIV pEV (Lee et al., 2016). Hence the bulk of viral particles
are produced by the T cell compartment. The relevance of liver infection
for HIV pathogenesis may lie in the persistence of the infection, the ac-
tivation of the resting T cell compartment by pEV and the transfer of
virus to T cells by cell to cell contact. The latter could explain the rapid
viral resurgence when treatment is interrupted, including the appear-
ance of archival virus subtypes after prolonged treatment (Shen and
Siliciano, 2008; Ruff et al., 2002).
Evidence for the relevance of HIV liver infection comes from clinical
ﬁndings. Chronic infection is associated with a number of hepatic disor-
ders ranging from elevated liver enzymes to liver cirrhosis (Ingiliz et al.,
2009; Weber et al., 2006). Currently these clinical symptoms are attrib-
uted to HBV/HCV co-infections, other co-morbidities and toxic drug ef-
fects (Blackard and Sherman, 2008; Weber et al., 2006). However, a
surprisingly strong but unexplained correlation was found between
low CD4 cell counts and liver-related deaths (Weber et al., 2006). We
described a correlation between low CD4 counts and ADAM17/Nef
levels in pEV, which likely correlates with the number of infected
hepatocytes. This would imply a connection between HIV infection of
liver cells, immunodeﬁciency and clinical symptoms. Hence targeting
HIV in the liver could be a new and promising avenue in treating the
disease.
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